Cilostazol suppresses β-amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1-coupled retinoic acid receptor-β

Journal of Neuroscience Research

Volumn 92, Issue 11, 2014, Pages 1581-1590

  Lee, Hye Rin ^a   Shin, Hwa Kyoung ^a   Park, So Youn ^a   Kim, Hye Young ^a   Lee, Won Suk ^a,b   Rhim, Byung Yong ^b   Hong, Ki Whan ^a   Kim, Chi Dae ^a,b  

^a Pusan National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

ADAM10; Alzheimer's disease; Cilostazol; SIRT1

Indexed keywords

ADAM10 ENDOPEPTIDASE; AMYLOID BETA PROTEIN; BETA SECRETASE; CILOSTAZOL; GAMMA SECRETASE; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; SIRTINOL; SIRTUIN 1; ADENOSINE-3',5'-CYCLIC PHOSPHOROTHIOATE; AMYLOID BETA PROTEIN[1-40]; BENZAMIDE DERIVATIVE; CYCLIC AMP; DISINTEGRIN; ENZYME INHIBITOR; NAPHTHOL DERIVATIVE; NEUROPROTECTIVE AGENT; NUCLEOTIDE; PEPTIDE FRAGMENT; RETINOIC ACID RECEPTOR; SECRETASE; SIRT1 PROTEIN, HUMAN; SMALL INTERFERING RNA; STROMELYSIN 2; TETRAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; ENZYME ACTIVITY; GENE; GENE OVEREXPRESSION; GENE SILENCING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SENILE PLAQUE; SIRT1 GENE; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NEUROBLASTOMA; PATHOLOGY; TIME; TUMOR CELL LINE; UPREGULATION;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BENZAMIDES; CELL LINE, TUMOR; CYCLIC AMP; DISINTEGRINS; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASE 10; MICE; NAPHTHOLS; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RECEPTORS, RETINOIC ACID; RNA, SMALL INTERFERING; SIRTUIN 1; TETRAZOLES; THIONUCLEOTIDES; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84906319574     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23421     Document Type: Article

References (27)

1. Amour A, Graham Knight CG, Webster A, Slocombe PM, Stephens PE, Knäupper V, Docherty AJP, Murphy G. 2000. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 473:275-279.
2. Anekonda TS, Reddy PH. 2006. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 96:305-313.
3. Araki T, Sasaki Y, Milbrandt J. 2004. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305:1010-1013.
4. Bell KF, Zheng L, Fahrenholz F, Cuello AC. 2008. ADAM-10 over-expression increases cortical synaptogenesis. Neurobiol Aging 29:554-565.
5. Corcoran JP, So PL, Maden M. 2004. Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci 20:896-902.
6. Donmez G, Wang D, Cohen DE, Guarente L. 2010. SIRT1 suppresses β-amyloid production by activating the α-secretase gene ADAM10. Cell 142:320-332.
7. Goodman AB. 2006. Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. J Cell Physiol 209:598-603.
8. Goodman AB, Pardee AB. 2003. Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc Natl Acad Sci U S A 100:2901-2905.
9. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
10. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191-196.
11. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N Jr, Bennett DA, Calon F. 2009. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68:48-74.
12. Kojro E, Gerald Gimpl G, Lammich S, März W, Fahrenholz F. 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM10. Proc Natl Acad Sci U S A 98:5815-5820.
13. Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, Hong KW, Kim CD. 2014. Attenuation of β-amyloid-induced tauopathy via activation of CK2α/SIRT1: targeting for cilostazol. J Neurosci Res 92:206-217.
14. Lee JH, Park SY, Shin YW, Hong KW, Kim CD, Sung SM, Kim KY, Lee WS. 2006. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res 1082:182-191.
15. Li Y, Hashimoto Y, Agadir A, Kagechika H, Zhang X. 1999. Identification of a novel class of retinoic acid receptor β-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J Biol Chem 274: 15360-15366.
16. Marcinkiewicz M, Seidah NG. 2000. Coordinated expression of beta-amyloid precursor protein and the putative β-secretase BACE and α-secretase ADAM10 in mouse and human brain. J Neurochem 75:2133-2143.
17. Mattson MP. 1997. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77:1081-1132.
18. Nunan J, Small DH. 2000. Regulation of APP cleavage by α-, β- and γ-secretases. FEBS Lett 483:6-10.
19. Outeiro TF, Marques O, Kazantsev A. 2008. Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta 1782:363-369.
20. Park SH, Kim JH, Bae SS, Hong KW, Lee DS, Leem JY, Choi BT, Shin HK. 2011. Protective effect of the phosphodiesterase III inhibitor cilostazol on β-amyloid-induced cognitive deficits associated with decreased amyloid β accumulation. Biochem Biophys Res Commun 408:602-608.
21. Patel NV, Gordon MN, Connor KE, Good RA, Engelman RW, Mason J, Morgan DG, Morgan TE, Finch CE. 2005. Caloric restriction attenuates Aβ-deposition in Alzheimer transgenic models. Neurobiol Aging 26: 995-1000.
22. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F. 2004. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113:1456-1464.
23. Prinzen C, Müller U, Endres K, Fahrenholz F, Postina R. 2005. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 19:1522-1524.
24. Qin W, Chachich M, Lane M, Roth G, Bryant M, de Cabo R, Ottinger MA, Mattison J, Ingram D, Gandy S, Pasinetti GM. 2006. Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in squirrel monkeys (Saimiri sciureus). J Alzheimers Dis 10:417-422.
25. Robert SJ, Zugaza JL, Fischmeister R, Gardier AM, Lezoualc'h F. 2001. The human serotonin 5-HT4 receptor regulates secretion of nonamyloidogenic precursor protein. J Biol Chem 276: 44881-44888.
26. Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F. 2009. Upregulation of the α-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J 23:1643-1654.
27. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, Maniar K, Dolios G, Wang R, Hof PR, Pasinetti GM. 2005. Caloric restriction attenuates β-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J 19:659-661.